N4 Pharma (N4P) Competitors GBX 0.56 -0.02 (-3.13%) As of 02/21/2025 11:39 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitors N4P vs. RGT, HELD, HLN, HIK, HCM, INDV, AMYT, APH, AGY, and BXPShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (RGT), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Allergy Therapeutics (AGY), and Beximco Pharmaceuticals (BXP). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Argent BioPharma Hellenic Dynamics Haleon Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Alliance Pharma Allergy Therapeutics Beximco Pharmaceuticals Argent BioPharma (LON:RGT) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking. Does the MarketBeat Community prefer RGT or N4P? N4 Pharma received 103 more outperform votes than Argent BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformArgent BioPharmaN/AN/AN4 PharmaOutperform Votes10365.61% Underperform Votes5434.39% Which has more volatility & risk, RGT or N4P? Argent BioPharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500. Does the media refer more to RGT or N4P? In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score. Company Overall Sentiment Argent BioPharma Neutral N4 Pharma Neutral Which has higher valuation & earnings, RGT or N4P? N4 Pharma has higher revenue and earnings than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArgent BioPharmaN/AN/A-£17.53M-£0.24N/AN4 Pharma£8.84K271.32-£1.63M-£0.35-1.61 Do insiders & institutionals believe in RGT or N4P? 1.1% of Argent BioPharma shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is RGT or N4P more profitable? Argent BioPharma has a net margin of -1,960.39% compared to N4 Pharma's net margin of -18,399.86%. Argent BioPharma's return on equity of 420.08% beat N4 Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Argent BioPharma-1,960.39% 420.08% -108.57% N4 Pharma -18,399.86%-90.68%-56.00% SummaryArgent BioPharma beats N4 Pharma on 6 of the 11 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.40M£2.35B£5.84B£2.64BDividend Yield3.12%2.92%4.75%4.98%P/E Ratio-1.614.2726.38162.45Price / Sales271.32733.09435.33313,812.36Price / Cash2.2510.2538.0128.15Price / Book1.247.507.645.16Net Income-£1.63M£20.70B£3.19B£5.75B7 Day Performance7.32%-0.11%-2.12%-1.02%1 Month Performance-13.64%0.00%-0.44%-0.86%1 Year Performance-25.73%97.98%16.30%39.56% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.56-3.1%N/A-23.2%£2.40M£8,841.37-1.615Gap UpRGTArgent BioPharmaN/AN/AN/AN/A£3.10MN/A-24.12N/AGap DownHigh Trading VolumeHELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A0.00N/AHLNHaleon0.4924 of 5 starsGBX 385.60-1.3%GBX 415+7.6%+20.4%£34.86B£11.26B3,213.3325,408High Trading VolumeHIKHikma Pharmaceuticals1.789 of 5 starsGBX 2,334-0.2%GBX 2,436.67+4.4%+15.6%£5.18B£3.02B3,590.779,100News CoverageHCMHUTCHMEDN/AGBX 206-2.4%N/A+11.8%£1.76B£610.81M-5,150.001,760Positive NewsGap UpINDVIndivior2.4978 of 5 starsGBX 793.50-2.6%GBX 1,650+107.9%-49.2%£1.02B£1.15B-991.881,000News CoverageAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma2.8367 of 5 starsGBX 61.46-0.1%GBX 6,250+10,069.9%+43.6%£332.21M£183.15M-1,024.2791,000AGYAllergy TherapeuticsN/AGBX 6.20-3.1%N/A+161.5%£295.74M£53.26M-103.33612BXPBeximco PharmaceuticalsN/AGBX 39.67+3.0%N/A-7.3%£176.97M£43.08B495.885,500Gap Up Related Companies and Tools Related Companies Argent BioPharma Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Alliance Pharma Alternatives Allergy Therapeutics Alternatives Beximco Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:N4P) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
